Predictors of metabolic monitoring among schizophrenia patients with a new episode of second-generation antipsychotic use in the Veterans Health Administration

BMC Psychiatry

Volumn 9, Issue , 2009, Pages

  Shi, Lizheng ^a,b,c   Ascher Svanum, Haya ^d   Chiang, Yi Ju ^a   Zhao, Yingnan ^a   Fonseca, Vivian ^b   Winstead, Daniel ^b  

^a TULANE UNIVERSITY   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; OBESITY; PREDICTION; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT DURATION; ADDICTION; BLOOD; CHEMICALLY INDUCED DISORDER; COMORBIDITY; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; GOVERNMENT; MALE; MEDICAL RECORD; METABOLISM; MONITORING; PREVALENCE; RISK FACTOR; STATISTICS; UNITED STATES; VETERAN;

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; COMORBIDITY; DIABETES MELLITUS; DYSLIPIDEMIAS; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MONITORING, PHYSIOLOGIC; PREVALENCE; RISK FACTORS; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS;

EID: 77949335580     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-9-80     Document Type: Article

References (29)

1. Newcomer JW. Metabolic syndrome and mental illness. J Manag Care 2007, 13(7 Suppl):S170-177.
2. Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, Weiden PJ, Cheskin LJ. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999, 60(4):215-220.
3. Homel P, Casey D, Allison DB. Changes in body mass index for individuals with and without schizophrenia, 1987-1996. Schizophr Res 2002, 55(3):277-284. 10.1016/S0920-9964(01)00256-0, 12048151.
4. Weiden PJ, Mackell JA, McDonnell DD. Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004, 66(1):51-57. 10.1016/S0920-9964(02)00498-X, 14693352.
5. Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull 2000, 26(4):903-912.
6. Mukherjee S, Decina P, Bocola V, Saraceni F, Scapicchio PL. Diabetes mellitus in schizophrenic patients. Compr Psychiatry 1996, 37(1):68-73. 10.1016/S0010-440X(96)90054-1, 8770530.
7. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001, 46(3):273-281.
8. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis 2006, 3(2):A42. 1563985, 16539783.
9. Graham KA, Cho H, Brownley KA, Harp JB. Early treatment-related changes in diabetes and cardiovascular disease risk markers in first episode psychosis subjects. Schizophr Res 2008, 101(1-3):287-294. 10.1016/j.schres.2007.12.476, 2443741, 18255275.
10. National Cholesterol Education Program. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults. , http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3_rpt.htm
11. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, . CLAMORS Study Collaborative Group Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res 2007, 90(1-3):162-173. 10.1016/j.schres.2006.09.025, 17123783, CLAMORS Study Collaborative Group.
12. Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, Lieberman JA. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008, 105(1-3):175-187. 10.1016/j.schres.2008.07.006, 2614656, 18775645.
13. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004, 161(8):1334-1349. 10.1176/appi.ajp.161.8.1334, 15285957.
14. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004, 65(2):267-272. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity.
15. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005, 80(1):19-32. 10.1016/j.schres.2005.07.014, 16137860.
16. Morrato EH, Newcomer JW, Allen RR, Valuck RJ. Prevalence of baseline serum glucose and lipid testing in users of second-generation antipsychotic drugs: a retrospective, population-based study of Medicaid claims data. J Clin Psychiatry 2008, 69(2):316-322. 10.4088/JCP.v69n0219, 18251625.
17. Jennex A, Gardner DM. Monitoring and management of metabolic risk factors in outpatients taking antipsychotic drugs: a controlled study. Can J Psychiatry 2008, 53(1):34-42.
18. Henderson K, Hudson T. Network-wide dissemination of antipsychotic monitoring protocol. MIRECC annual meeting. New Orleans 2005,
19. Lipkovich I, Jacobson JG, Hardy TA, Hoffmann VP. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 2008, 8:78. 10.1186/1471-244X-8-78, 2566555, 18793440.
20. Kinon BJ, Kaiser CJ, Ahmed S, Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005, 25(3):255-258. 10.1097/01.jcp.0000161501.65890.22, 15876905.
21. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40(5):373-383. 10.1016/0021-9681(87)90171-8, 3558716.
22. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. BMJ 1995, 311(6998):158-161. 2550221, 7613427.
23. Zhu S, Wang Z, Heshka S, Heo M, Faith MS, Heymsfield SB. Waist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholds. Am J Clin Nutr 2002, 76(4):743-749.
24. Calculate Your Body Mass Index. Accessed on March 30 2008., http://www.nhlbisupport.com/bmi
25. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P, . Expert Committee on the Diagnosis and Classification of Diabetes Mellitus Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26(11):3160-3167. 10.2337/diacare.26.11.3160, 14578255, Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
26. Grundy SM, Brewer HB, Cleeman JI, Smith SC, Lenfant C, . American Heart Association, National Heart, Lung and Blood Institute Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438. 10.1161/01.CIR.0000111245.75752.C6, 14744958, American Heart Association, National Heart, Lung and Blood Institute.
27. Sernyak MJ. Implementation of monitoring and management guidelines for second-generation antipsychotics. J Clin Psychiatry 2007, 68(Suppl 4):14-18.
28. Morrato EH, Cuffel B, Newcomer JW, Lombardo I, Kamat S, Barron J. Metabolic risk status and second-generation antipsychotic drug selection: a retrospective study of commercially insured patients. J Clin Psychopharmacol 2009, 29(1):26-32. 10.1097/JCP.0b013e31819294cb, 19142103.
29. Haupt DW, Rosenblatt LC, Kim E, Baker RA, Whitehead R, Newcomer JW. Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treatment with second-generation antipsychotic agents. Am J Psychiatry 2009, 166:345-353. 10.1176/appi.ajp.2008.08030383, 19147694.